Perspectives for the pharmacological treatment of overactive bladder syndrome.

Ginekol Pol

Second Department of Gynecology, Medical University of Lublin,, Jaczewskiego 8, PL 20-090 Lublin, Poland, 20-090, Lublin, Poland.

Published: July 2018

It has been found that antimuscarinic drugs, viewed as the "gold standard" in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.a2017.0092DOI Listing

Publication Analysis

Top Keywords

overactive bladder
8
bladder syndrome
8
perspectives pharmacological
4
pharmacological treatment
4
treatment overactive
4
syndrome antimuscarinic
4
antimuscarinic drugs
4
drugs viewed
4
viewed "gold
4
"gold standard"
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!